- Home
- SIBN vs CGEM Comparison
SIBN vs CGEM Comparison
Compare SIBN & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIBN
- CGEM
- Stock Information
- Founded
- SIBN 2008
- CGEM 2016
- Country
- SIBN United States
- CGEM United States
- Employees
- SIBN N/A
- CGEM N/A
- Industry
- SIBN Medical/Dental Instruments
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- SIBN Health Care
- CGEM Health Care
- Exchange
- SIBN Nasdaq
- CGEM Nasdaq
- Market Cap
- SIBN 571.0M
- CGEM 490.3M
- IPO Year
- SIBN 2018
- CGEM 2021
- Fundamental
- Price
- SIBN $18.49
- CGEM $7.54
- Analyst Decision
- SIBN Strong Buy
- CGEM Strong Buy
- Analyst Count
- SIBN 5
- CGEM 4
- Target Price
- SIBN $24.40
- CGEM $33.50
- AVG Volume (30 Days)
- SIBN 483.4K
- CGEM 465.9K
- Earning Date
- SIBN 05-05-2025
- CGEM 05-08-2025
- Dividend Yield
- SIBN N/A
- CGEM N/A
- EPS Growth
- SIBN N/A
- CGEM N/A
- EPS
- SIBN N/A
- CGEM N/A
- Revenue
- SIBN $176,601,000.00
- CGEM N/A
- Revenue This Year
- SIBN $18.52
- CGEM N/A
- Revenue Next Year
- SIBN $16.39
- CGEM N/A
- P/E Ratio
- SIBN N/A
- CGEM N/A
- Revenue Growth
- SIBN 22.60
- CGEM N/A
- 52 Week Low
- SIBN $11.70
- CGEM $6.85
- 52 Week High
- SIBN $19.16
- CGEM $30.19
- Technical
- Relative Strength Index (RSI)
- SIBN 78.21
- CGEM 41.51
- Support Level
- SIBN $13.64
- CGEM $7.50
- Resistance Level
- SIBN $18.91
- CGEM $8.97
- Average True Range (ATR)
- SIBN 0.77
- CGEM 0.48
- MACD
- SIBN 0.58
- CGEM -0.04
- Stochastic Oscillator
- SIBN 92.53
- CGEM 2.72
About SIBN SI-BONE Inc.
SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.